Literature DB >> 18180404

Novel role of protein kinase C-delta Tyr 311 phosphorylation in vascular smooth muscle cell hypertrophy by angiotensin II.

Hidekatsu Nakashima1, Gerald D Frank, Heigoro Shirai, Akinari Hinoki, Sadaharu Higuchi, Haruhiko Ohtsu, Kunie Eguchi, Archana Sanjay, Mary E Reyland, Peter J Dempsey, Tadashi Inagami, Satoru Eguchi.   

Abstract

We have shown previously that activation of protein kinase C-delta (PKC delta) is required for angiotensin II (Ang II)-induced migration of vascular smooth muscle cells (VSMCs). Here, we have hypothesized that PKC delta phosphorylation at Tyr(311) plays a critical role in VSMC hypertrophy induced by Ang II. Immunoblotting was used to monitor PKC delta phosphorylation at Tyr(311), and cell size and protein measurements were used to detect hypertrophy in VSMCs. PKC delta was rapidly (0.5 to 10.0 minutes) phosphorylated at Tyr(311) by Ang II. This phosphorylation was markedly blocked by an Src family kinase inhibitor and dominant-negative Src but not by an epidermal growth factor receptor kinase inhibitor. Ang II-induced Akt phosphorylation and hypertrophic responses were significantly enhanced in VSMCs expressing PKC delta wild-type compared with VSMCs expressing control vector, whereas the enhancements were markedly diminished in VSMCs expressing a PKC delta Y311F mutant. Also, these responses were significantly inhibited in VSMCs expressing kinase-inactive PKC delta K376A compared with VSMCs expressing control vector. From these data, we conclude that not only PKC delta kinase activation but also the Src-dependent Tyr(311) phosphorylation contributes to Akt activation and subsequent VSMC hypertrophy induced by Ang II, thus signifying a novel molecular mechanism for enhancement of cardiovascular diseases induced by Ang II.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180404      PMCID: PMC2728048          DOI: 10.1161/HYPERTENSIONAHA.107.101253

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  59 in total

1.  PKCdelta is required for mitochondrial-dependent apoptosis in salivary epithelial cells.

Authors:  A A Matassa; L Carpenter; T J Biden; M J Humphries; M E Reyland
Journal:  J Biol Chem       Date:  2001-05-21       Impact factor: 5.157

Review 2.  Proteomics and metabolomics combined in cardiovascular research.

Authors:  Manuel Mayr; Basetti Madhu; Qingbo Xu
Journal:  Trends Cardiovasc Med       Date:  2007-02       Impact factor: 6.677

3.  Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice.

Authors:  M Leitges; M Mayr; U Braun; U Mayr; C Li; G Pfister; N Ghaffari-Tabrizi; G Baier; Y Hu; Q Xu
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats.

Authors:  Rhian M Touyz; Xiao-Hua Wu; Gang He; Steven Salomon; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

5.  Mechanism of endothelial nitric oxide synthase phosphorylation and activation by thrombin.

Authors:  Evangeline D Motley; Kunie Eguchi; Myla M Patterson; Phillip D Palmer; Hiroyuki Suzuki; Satoru Eguchi
Journal:  Hypertension       Date:  2007-01-08       Impact factor: 10.190

6.  Temporal expression of heat shock proteins 60 and 70 at lesion-prone sites during atherogenesis in ApoE-deficient mice.

Authors:  R K Kanwar; J R Kanwar; D Wang; D J Ormrod; G W Krissansen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

7.  Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.

Authors:  S Wakino; U Kintscher; Z Liu; S Kim; F Yin; M Ohba; T Kuroki; A H Schönthal; W A Hsueh; R E Law
Journal:  J Biol Chem       Date:  2001-10-11       Impact factor: 5.157

8.  Requirement of Ca(2+) and PKCdelta for Janus kinase 2 activation by angiotensin II: involvement of PYK2.

Authors:  Gerald D Frank; Shuichi Saito; Evangeline D Motley; Terukatsu Sasaki; Motoi Ohba; Toshio Kuroki; Tadashi Inagami; Satoru Eguchi
Journal:  Mol Endocrinol       Date:  2002-02

Review 9.  Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta.

Authors:  Stephen P Soltoff
Journal:  Trends Pharmacol Sci       Date:  2007-08-10       Impact factor: 14.819

10.  Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells.

Authors:  Arshad Rahman; Andrea L True; Khandaker N Anwar; Richard D Ye; Tatyana A Voyno-Yasenetskaya; Asrar B Malik
Journal:  Circ Res       Date:  2002-09-06       Impact factor: 17.367

View more
  21 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.

Authors:  Cuneyt K Buharalioglu; Chi Young Song; Fariborz A Yaghini; Hafiz U B Ghafoor; Mustafa Motiwala; Tusita Adris; Anne M Estes; Kafait U Malik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-03       Impact factor: 4.733

3.  The C2 Domain and Altered ATP-Binding Loop Phosphorylation at Ser³⁵⁹ Mediate the Redox-Dependent Increase in Protein Kinase C-δ Activity.

Authors:  Jianli Gong; Yongneng Yao; Pingbo Zhang; Barath Udayasuryan; Elena V Komissarova; Ju Chen; Sivaraj Sivaramakrishnan; Jennifer E Van Eyk; Susan F Steinberg
Journal:  Mol Cell Biol       Date:  2015-03-09       Impact factor: 4.272

Review 4.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

5.  Protein kinase C-{delta} regulates the subcellular localization of Shc in H2O2-treated cardiomyocytes.

Authors:  Jianfen Guo; Lin Cong; Vitalyi O Rybin; Zoya Gertsberg; Susan F Steinberg
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-04       Impact factor: 4.249

6.  β-Adrenergic receptors stimulate interleukin-6 production through Epac-dependent activation of PKCδ/p38 MAPK signalling in neonatal mouse cardiac fibroblasts.

Authors:  Chao Chen; Jianhai Du; Wei Feng; Yao Song; Zhizhen Lu; Ming Xu; Zijian Li; Youyi Zhang
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II.

Authors:  Akira Takaguri; Heigoro Shirai; Keita Kimura; Akinari Hinoki; Kunie Eguchi; MaryEllen Carlile-Klusacek; Baohua Yang; Victor Rizzo; Satoru Eguchi
Journal:  J Mol Cell Cardiol       Date:  2010-12-21       Impact factor: 5.000

8.  PKCδ Mediates Mineralocorticoid Receptor Activation by Angiotensin II to Modulate Smooth Muscle Cell Function.

Authors:  Qing Lu; Ana P Davel; Adam P McGraw; Sitara P Rao; Brenna G Newfell; Iris Z Jaffe
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

9.  Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR.

Authors:  Anke Doller; Kai Schlepckow; Harald Schwalbe; Josef Pfeilschifter; Wolfgang Eberhardt
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

10.  ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.

Authors:  Katherine J Elliott; Allison M Bourne; Takehiko Takayanagi; Akira Takaguri; Tomonori Kobayashi; Kunie Eguchi; Satoru Eguchi
Journal:  J Mol Cell Cardiol       Date:  2013-05-17       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.